Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Immune-Mediated Rheumatic Diseases
share announcement

Immune-Mediated Rheumatic Diseases

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Immunology".

Deadline for manuscript submissions: closed (15 October 2023) | Viewed by 3263

Special Issue Editor

Dr. Daniela Opriş-Belinski

E-Mail Website
Guest Editor
Department of Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Interests: autoimmune disorders; inflammatory diseases; biologicals; connective tissue disorders; spondyloarthitis
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

It gives me great pleasure to announce the opening of the submission of articles for this new "Journal of Clinical Medicine" Special Issue on the theme "Immune-mediated Rheumatic Diseases". This topic was chosen because the heterogeneity of the multisystemic involvement and comorbidities; paraclinical particularities; and (last but not least) the increased potential for morbidity, mortality, and disability are challenges for any doctor involved in their treatment. The complexity of these conditions explains the frequent need for monitoring, therapeutic adjustment, and multidisciplinary team approaches. Fortunately, it can be said without exaggeration that recent years have brought amazing therapeutic advances that have significantly changed the management and prognosis of these patients. 

We welcome the submission of original research and review articles on the following topics:

  • Diagnostic tools;
  • Clinical and immunological correlations;
  • Therapeutic challenges;
  • Risk stratification;
  • Achieving goals in management and treatment;
  • Old and new therapeutic targets;
  • Comorbidities (diagnosis, correlations, and management).

Dr. Daniela Opriş-Belinski
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • rheumatoid arthritis
  • systemic lupus
  • scleroderma
  • Sjögren’s syndrome
  • mixed connective tissue disease
  • vasculitis
  • spondyloarthritis
  • psoriatic arthritis

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 6239 KiB  
Article
Total Globulin Fraction at Diagnosis Could Forecast All-Cause Mortality during the Disease Course in Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
by Jang-Woo Ha, Sung-Soo Ahn, Jason-Jungsik Song, Yong-Beom Park and Sang-Won Lee
J. Clin. Med. 2023, 12(12), 4170; https://doi.org/10.3390/jcm12124170 - 20 Jun 2023
Viewed by 1008
Abstract
Total globulin fraction (TGF) is calculated by subtracting serum albumin levels from serum total protein levels. The present study examined whether TGF at diagnosis could forecast all-cause mortality during the disease course in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The present [...] Read more.
Total globulin fraction (TGF) is calculated by subtracting serum albumin levels from serum total protein levels. The present study examined whether TGF at diagnosis could forecast all-cause mortality during the disease course in patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The present study included 283 patients with AAV. The variables at AAV diagnosis such as demographic data, AAV-specific data including the Birmingham vasculitis activity score (BVAS), five-factor score (FFS), and laboratory data including ANCA, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were collected. The number of deceased patients during the follow-up duration based on all-cause mortality was counted. The median age of the 283 AAV patients was 60 years, and 35.7% were men. ANCAs were detected in 228 patients, and the median TGF was 2.9. A total of 39 patients (13.8%) died within a median follow-up duration of 46.9 months. TGF at AAV diagnosis was significantly correlated with ESR and CRP rather than AAV activity. Patients with ANCA positivity exhibited a significantly higher median TGF at AAV diagnosis than those without. Patients with TGF ≥ 3.1 g/dL at AAV diagnosis exhibited a significantly lower cumulative survival rate than those without. Furthermore, in the multivariable Cox hazards model analysis, TGF ≥ 3.1 g/dL (hazard ratio 2.611) was independently associated with all-cause mortality, along with age, male sex, and body mass index. The present study is the first to demonstrate that TGF at AAV diagnosis can forecast all-cause mortality during the disease course in AAV patients. Full article
(This article belongs to the Special Issue Immune-Mediated Rheumatic Diseases)
►▼ Show Figures

Figure 1

Other

Jump to: Research

19 pages, 1658 KiB  
Systematic Review
The Physical and Psychosocial Impact of Fatigue among Patients with Sjogren’s Syndrome: A Systematic Review
by Denise-Ani Mardale, Daniela Opriș-Belinski, Violeta Bojincă, Mihai Bojincă, Diana Mazilu, Emilia Păsăran, Cristina Nițăa, Laura Groșeanu, Florian Berghea and Andra-Rodica Bălănescu
J. Clin. Med. 2024, 13(6), 1537; https://doi.org/10.3390/jcm13061537 - 7 Mar 2024
Viewed by 704
Abstract
Background: Primary Sjögren’s syndrome (pSS) is a complex autoimmune disorder characterized by organ-specific symptoms in the salivary and lacrimal glands, as well as systemic manifestations. Fatigue, a prominent aspect, significantly influences the overall quality of life for individuals with pSS. Methods: This review [...] Read more.
Background: Primary Sjögren’s syndrome (pSS) is a complex autoimmune disorder characterized by organ-specific symptoms in the salivary and lacrimal glands, as well as systemic manifestations. Fatigue, a prominent aspect, significantly influences the overall quality of life for individuals with pSS. Methods: This review seeks to evaluate the impact of fatigue by exploring its consequences, potential causes, and effects on physical and psychological well-being, while also investigating its management strategies. Following the “Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)” guidelines, our systematic literature review involved a five-step algorithm. Initially identifying 78 articles in reputable international medical databases, we applied eligibility criteria and removed duplicates, resulting in 19 articles for qualitative synthesis. Results: This review delves into the predictive factors for heightened fatigue in pSS, encompassing rheumatoid factor levels, erythrocyte sedimentation rate, and immunoglobulin G levels. Sleep disturbances, specifically nighttime pain and nocturia, emerged as determinants of persistent daytime fatigue. Cognitive impairment in pSS involves deteriorations in global memory, executive functioning, and attentional resources. Furthermore, functional limitations in pSS impact patients’ quality of life. Conclusions: The significance of fatigue in pSS, its consequences, and profound influence on the quality of life necessitate further research for a more comprehensive understanding of this complex issue. Full article
(This article belongs to the Special Issue Immune-Mediated Rheumatic Diseases)
►▼ Show Figures

Figure 1

14 pages, 1041 KiB  
Systematic Review
Therapeutic Potential of Rituximab in Managing Hepatitis C-Associated Cryoglobulinemic Vasculitis: A Systematic Review
by Andreea Covic, Irina Draga Caruntu, Alexandru Burlacu, Simona Eliza Giusca, Adrian Covic, Anca Elena Stefan, Crischentian Brinza and Gener Ismail
J. Clin. Med. 2023, 12(21), 6806; https://doi.org/10.3390/jcm12216806 - 27 Oct 2023
Viewed by 1161
Abstract
(1) Background. Hepatitis C infection often leads to extrahepatic manifestations, including cryoglobulinemic vasculitis. This systematic review aimed to assess the efficacy and safety of rituximab in treating hepatitis C-associated cryoglobulinemic vasculitis. (2) Methods. Following PRISMA guidelines, databases were searched for relevant studies. Eligibility [...] Read more.
(1) Background. Hepatitis C infection often leads to extrahepatic manifestations, including cryoglobulinemic vasculitis. This systematic review aimed to assess the efficacy and safety of rituximab in treating hepatitis C-associated cryoglobulinemic vasculitis. (2) Methods. Following PRISMA guidelines, databases were searched for relevant studies. Eligibility criteria included studies on hepatitis C-associated cryoglobulinemic vasculitis treated with rituximab. (3) Results. Nine studies met the eligibility criteria and were included in this analysis. Rituximab was commonly administered at 375 mg/m2 weekly for one month. The results consistently demonstrated the efficacy of rituximab, whether as a standalone treatment or as part of a therapeutic regimen. The combination of rituximab with Peg-IFN-α and ribavirin significantly increased the complete response rate compared to Peg-IFN-α and ribavirin alone (54.5% vs. 33.3%, p < 0.05). The 3-year sustained response rate was notably higher in the rituximab combination group (83.3% vs. 40%). In another trial, rituximab achieved remission in 83.3% of patients at 6 months, compared to only 8.3% in the control group. The efficacy of rituximab was supported by long-term experience, with clinical benefits in patients with severe cryoglobulinemic vasculitis, including those resistant to standard therapies. Mild adverse events were generally reported, with rare severe reactions in some studies. (4) Conclusions: In conclusion, rituximab appeared to be effective and safe in managing hepatitis C-associated cryoglobulinemic vasculitis, either alone or with antiviral therapy. Full article
(This article belongs to the Special Issue Immune-Mediated Rheumatic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop